Cleveland Biolabs (CBLI) Stock Price, Quote, News and Overview
NASDAQ:CBLI - Nasdaq -
CBLI Quote, Performance and Key Statistics
3.17
-0.25 (-7.31%)
The current stock price of CBLI is 3.17 null. In the past month the price decreased by -10.96%. In the past year, price increased by 72.28%.
CBLI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CBLI
Company Profile
Cytocom Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Fort Collins, Colorado and currently employs 2 full-time employees. The company went IPO on 2006-07-21. Cytocom, Inc., formerly Cleveland BioLabs, Inc., is a clinical-stage biopharmaceutical company. The firm is focused on developing small molecule immunotherapies, which targets autoimmune, inflammatory, infectious diseases and cancers. Its advanced immunomodulating multi-receptor system (AIMS) platform is a drug discovery and development platform, which is designed to restore immune homeostasis. Its immunomodulatory drugs are developed using AIMS platform, which adjusts immune responses to halt or slow disease progression. Its clinical-stage development programs are focused on treating Crohn's disease, fibromyalgia, multiple sclerosis and pancreatic cancer. The Company’s programs include CYTO-200 AIMS Program, CYTO-400 AIMS Program and CYTO-600 Program. The firm also has a platform of toll-like immune receptors (TLR4, TLR5 and TLR9), which address the conditions such as radiation sickness and cancer treatment side effects.
Company Info
Cleveland Biolabs
2537 Research Boulevard, Suite 201
Fort Collins COLORADO 14203 US
CEO: Christopher Zosh
Employees: 2
Company Website: https://www.cytocom.com/
Phone: 18886138802.0
Cleveland Biolabs / CBLI FAQ
What is the stock price of Cleveland Biolabs today?
The current stock price of CBLI is 3.17 null. The price decreased by -7.31% in the last trading session.
What is the ticker symbol for Cleveland Biolabs stock?
The exchange symbol of Cleveland Biolabs is CBLI and it is listed on the Nasdaq exchange.
On which exchange is CBLI stock listed?
CBLI stock is listed on the Nasdaq exchange.
What is Cleveland Biolabs worth?
Cleveland Biolabs (CBLI) has a market capitalization of 49.07M null. This makes CBLI a Nano Cap stock.
How many employees does Cleveland Biolabs have?
Cleveland Biolabs (CBLI) currently has 2 employees.
What are the support and resistance levels for Cleveland Biolabs (CBLI) stock?
Cleveland Biolabs (CBLI) has a support level at 3.06 and a resistance level at 3.33. Check the full technical report for a detailed analysis of CBLI support and resistance levels.
Should I buy Cleveland Biolabs (CBLI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CBLI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CBLI, evaluating the profitability, health, valuation and growth aspects
- Cleveland Biolabs (CBLI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Cleveland Biolabs (CBLI) Sales and EPS estimates to see what analysts future expectations are.
- Cleveland Biolabs (CBLI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Cleveland Biolabs (CBLI) Insider and Institutional Ownership to learn about the owners and their transactions.
- Cleveland Biolabs (CBLI) Stock Chart to make your own analysis
- Cleveland Biolabs (CBLI) Latest news and press-releases to stay up to date.
Does Cleveland Biolabs (CBLI) stock pay dividends?
CBLI does not pay a dividend.
What is the Price/Earnings (PE) ratio of Cleveland Biolabs (CBLI)?
Cleveland Biolabs (CBLI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.19).
CBLI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CBLI. When comparing the yearly performance of all stocks, CBLI turns out to be only a medium performer in the overall market: it outperformed 54.61% of all stocks.
CBLI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CBLI. No worries on liquidiy or solvency for CBLI as it has an excellent financial health rating, but there are worries on the profitability.
CBLI Financial Highlights
Over the last trailing twelve months CBLI reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS decreased by -5.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -6049.77% | ||
| ROA | -19.07% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |